Rheumatoid arthritis


Tocilizumab in methotrexate-naïve rheumatoid arthritis: a cost-utility model for Slovakia

Value in Health. 2015;18(7):A648


Chang S, Sawyer L, Dejonckheere F, Grichova L, Diamantopoulos A


For more information about health economic modelling or to request a quote please contact Alex Diamantopoulos at info@symmetron.net 

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke


Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK


Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective